Research Article Acceptability of Human Papillomavirus Vaccine: A Survey among Master of Business Administration Students in KwaZulu-Natal, South Africa Muhammad Ehsanul Hoque 1 and Guido Van Hal 2 1 Graduate School of Business and Leadership, University of KwaZulu-Natal, Durban 4000, South Africa 2 Medical Sociology and Health Policy, University of Antwerp, Antwerp 2610, Belgium Correspondence should be addressed to Muhammad Ehsanul Hoque; hoque@ukzn.ac.za Received 8 April 2014; Accepted 8 July 2014; Published 5 August 2014 Academic Editor: Massimo Origoni Copyright © 2014 M. E. Hoque and G. Van Hal. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cervical cancer is a preventable public health problem. Te two new human papillomavirus (HPV) vaccines are available but not accessible to everyone in South Africa, as they are very expensive. Tis study aimed to investigate educated peoples acceptability regarding HPV vaccination. Tis was a cross-sectional survey conducted among 146 master of business administration students by self-administered, anonymous questionnaire. Te majority (74%) of the participants ever heard of cervical cancer, but only 26.2% heard about HPV. Afer reading the fact information regarding cervical cancer and HPV, the intention to vaccinate their daughters increased from 88% to 97.2% ( = 0.003). Te majority (75.4%) indicated that HPV vaccination should be given before their daughters are mature enough to understand about sex, and 80.3% reported that they will discuss matters related to sex with their daughters if their daughters want to know about the vaccine. Tose who did not want to vaccinate their daughters highlighted that they want more information regarding safety of the vaccine which might change their decision towards HPV vaccination. A health education information method can increase the vaccination acceptance rate in South Africa. 1. Introduction Cervical cancer is a preventable disease, but it accounts for around 275,100 deaths, and more than half a million women are diagnosed each year in the world [1]. In South Africa, it is also the second common cancer afer breast cancer. It is reported that at least 3,000 women die from cervical cancer every year, and by the year 2025, at least 4,000 women will die from cervical cancer in South Africa [2]. Because of unequal access to healthcare, diferences in socioeconomic status, and exposure to HPV and HIV infection, black women are disproportionately afected [3, 4]. Cervical cancer screening in South Africa is free for women over 30 years of age as to achieve 70% coverage of this age group. But the screening in this group of women is below 20%. A recent study conducted from January 2007 to December 2010 found that annual screening coverage was between 2.9% and 4.2% [5]. Another study conducted among women who were diagnosed and managed at a Gynecological Oncology unit in South Africa reported that about 40% of women had a gynecological exam- ination at their frst visit and 15% were referred appropriately [6]. Tanks to the new development of a HPV vaccine with high efcacy, cervical cancer incidence can signifcantly be reduced (with 70%) if a comprehensive vaccination program could be implemented [7–9]. Many countries that have low cervical cancer rates have already implemented country wide HPV vaccination programs. But full coverage was not achieved in any country. A survey conducted in the USA in 2010 reported that 60% of parents were not interested or not sure to vaccinate their daughters [10]. School-based vaccina- tion programs have the highest vaccination coverage in many countries like Spain, Scotland, England, and Te Netherlands [11–14]. Te most notable fnding was that in Uganda, where a well-planned school-based campaign achieved about 95% coverage in the country [15]. Te two vaccines, Cervarix (a bivalent vaccine) and Gar- dasil (the quadrivalent vaccine), are currently available in Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 257807, 6 pages http://dx.doi.org/10.1155/2014/257807